De novo metabolic syndrome after liver transplantation: a meta-analysis on cumulative incidence, risk factors, and outcomes

Lim, Wen Hui; Tan, Char Loo; Xiao, Jieling; Tan, Darren Jun Hao; Ng, Cheng Han; Yong, Jie Ning; Fu, Clarissa Elysia; Chan, Kai En; Zeng, Rebecca Wenling; Ren, Yi; Goh, Xin Lei; Chew, Nicholas; Tseng, Michael T.; Syn, Nicholas; Mak, Lung‐Yi; Muthiah, Mark; Siddiqui, Mohammad Shadab; Tan, Eunice X.

doi:10.1097/lvt.0000000000000004

Cited by 5 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While arterial hypertension is one of the most prevalent cardiovascular risk factors in the general population, the incidence of post-liver transplantation hypertension is remarkably high, ranging between 50% and 80%, as reported by some studies [4,18,19]. The onset of de novo arterial hypertension post liver transplantation, as reported in a study conducted by de Oliveira Lemos et al [20], occurred at an average of 9 ± 6.98 months.…”

Section: Arterial Hypertensionmentioning

confidence: 90%

Metabolic Disorders in Liver Transplant Recipients: The State of the Art

Gabrielli,

Golfieri,

Nascimbeni

et al. 2024

JCM

View full text Add to dashboard Cite

Liver transplantation represents a chief therapeutic approach for acute liver failure, end-stage liver disease and hepatocellular carcinoma. Despite witnessing advancements in short- and medium-term survival over recent decades, attributed to refinements in surgical techniques and immunosuppressive protocols, long-term mortality remains impervious to modification. Notably, cardiovascular disease emerges as a predominant cause of mortality among liver transplant recipients. This trend is accentuated by the increasing prominence of non-alcoholic steatohepatitis-related cirrhosis as an indication for liver transplantation. Moreover, the administration of immunosuppressive agents is intricately linked to the degradation of the metabolic profile in liver transplant recipients, thereby contributing to the initiation or exacerbation of cardiovascular risk factors, such as hypertension, diabetes, and dyslipidaemia. In addition, the post-liver transplantation period is marked by a decline in lifestyle quality and a failure to acknowledge the psychological distress experienced by patients throughout the transplant process. These factors can precipitate a deterioration in the patient’s metabolic profile, exacerbated by suboptimal therapeutic compliance. This narrative review aims to comprehensively address the principal metabolic disorders intricately associated with liver transplantation.

show abstract

Section: Arterial Hypertensionmentioning

confidence: 90%

Metabolic Disorders in Liver Transplant Recipients: The State of the Art

Gabrielli,

Golfieri,

Nascimbeni

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…There is a paucity of scientific reports that provide evidence on the influence of new-onset MS on mid- and long-term prognoses in liver recipients. Those that exist suggest increased cardiovascular (CV) morbidity with no implications for survival rates and risk of de novo tumours [ 7 , 8 , 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

De Novo Metabolic Syndrome 1 Year after Liver Transplantation and Its Association with Mid- and Long-Term Morbidity and Mortality in Liver Recipients

Czarnecka,

Tronina

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Metabolic syndrome (MS) constitutes an important source of cardiovascular- and cancer-related morbidity and mortality in the general population. Limited information is available on whether these findings can be directly extrapolated to liver recipients. This study aimed to investigate the impact of post-transplant MS present 1 year after liver transplantation on survival rates, risk of major cardiovascular events (CVEs), and de novo malignancies. Methods: Adult deceased-liver-donor recipients who underwent transplantation in our centre between 2010 and 2019 and reached at least 1 year of post-transplantation follow-up were eligible. Results: Of 259 enrolled patients, 20% developed post-transplant MS 1 year after the procedure. The presence of post-transplant MS at 1 year did not affect all-cause mortality (p = 0.144) and risk of de novo malignancies (p = 0.198) in liver recipients. However, it was associated with an overall and time-dependent increase in the risk of major CVEs (p < 0.001). MASH aetiology of liver disease, pre-existing major CVEs, and development of de novo malignancy were independent predictors of all-cause mortality in liver recipients. Conclusions: New onset MS exerts a wide-ranging effect on the post-transplant prognosis of liver recipients. Obtaining optimal control over all modifiable metabolic risk factors is central to improving long-term outcomes in this population.

show abstract

MASH Continues as a Significant Burden on Metabolic Health of Liver Recipients

Czarnecka,

Tronina

et al. 2024

Transplantation Proceedings

View full text Add to dashboard Cite

De novo metabolic syndrome after liver transplantation: a meta-analysis on cumulative incidence, risk factors, and outcomes

Cited by 5 publications

References 56 publications

Metabolic Disorders in Liver Transplant Recipients: The State of the Art

Metabolic Disorders in Liver Transplant Recipients: The State of the Art

De Novo Metabolic Syndrome 1 Year after Liver Transplantation and Its Association with Mid- and Long-Term Morbidity and Mortality in Liver Recipients

MASH Continues as a Significant Burden on Metabolic Health of Liver Recipients

Contact Info

Product

Resources

About